Hematology, Transfusion and Cell Therapy (Dec 2024)

PAGET SCHROETTER SYNDROME AND HOMOZYGOUS FACTOR V LEIDEN MUTATION: A CASE PRESENTATION

  • Damla Cagla Patır,
  • Nigar Abdullayeva,
  • Dogus Berk Kuzucu,
  • Mahmut Tobu

Journal volume & issue
Vol. 46
p. S54

Abstract

Read online

Case Report: Thrombosis in the deep veins of the upper extremity accounts for only 5% of symptomatic cases but constitutes approximately 50% of hospital-acquired thromboses. The vast majority of upper extremity thromboses, result from the presence of permanent venous catheter. Unprovoked cases are often secondary to ''effort'' thrombosis. Here, we present a case of Paget-Schroetter syndrome combined with a homozygous mutation of factor V Leiden.A 19-year-old female patient presented with pain and swelling in her right arm. The report of the right arm venous Doppler ultrasound indicated the presence of thrombus within the lumen at the proximal and distal segments of the basilic vein at the fossa cubiti level. The patient was found to have a homozygous mutation of factor V Leiden, and it was learned that she had been undergoing intense training and was engaged in water polo for the last two months. She had no history of medication use or chronic illnesses, nor any previous history of thrombosis. The patient was started on low molecular weight heparin for three months. A control Doppler ultrasound showed that the existing thrombus had resolved. It was recommended that the patient continue on her current anticoagulation with a new generation oral anticoagulant for one year. During this period, the patient, who ceased sports activities, did not develop any new thrombosis.The combination of young age, intense physical activity, especially in sports that utilize the upper extremities, and risk factors such as the factor V Leiden mutation strengthens the diagnosis. In the pathophysiology of this syndrome, vascular microtravma and exercise, muscle hypertrophy and thrombophilias contribute to the condition. Low molecular weight heparin and new generation oral anticoagulants are effective in preventing thrombosis formation and in inhibiting the growth of existing thrombus. Thrombolytic therapy may be considered in cases of large thromboses or severe symptoms.